Takeda-backed Ascentage Pharma Group (AAPG) (ASPHF), which is developing treatments for blood cancers, has set terms for a $170M U.S. initial public offering. Read more here.

Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

Ascentage Pharma Hogan.Wan@ascentage.com +86 512 85557777 Stephanie Carrington ICR Healthcare Stephanie.Carrington@icrhealthcare.com (646) 277-1282 Media Relations Sean Leous ICR Healthcare ...

Ascentage Pharma Group Corp. Ltd. has priced the first IPO of the year in the U.S. The offering of 7.32 million shares has the Suzhou, China, and Rockville, Md.-based company looking for gross ...

Dajun Yang is co-founder, chairman and CEO of Ascentage Pharma, a Chinese clinical-stage company with a U.S. headquarters in Rockville.

Ascentage Pharma Rings the Opening Bell 0 of 17 minutes, 0Volume 0% ... January 24, 2025 — 9:15 AM - 9:45 AM ET Nasdaq MarketSite, 4 Times Square, New York ...

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment.

Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market ...

Ascentage Pharma Group International (NASDAQ:AAPG) announced the appointments of Veet Misra as the company’s CFO, and Eric Huang, as Senior Vice President of Global Corporate Development and ...

In addition, Ascentage Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,098,750 ADSs at the initial public offering price, less underwriting discounts and ...